Sustained improvement in health‐related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti‐tumor necrosis factor therapy

Abstract

Improvements in HRQoL for IBD patients on anti-TNF therapy were sustained for longer than one year. HRQoL measures for IBD patients treated with anti-TNF therapy for <1 year do not differ significantly from those treated for ≥1 year, but a trend towards improved HRQoL measures with prolonged therapy can be obtained.

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

“…Th e group agreed that the ultimate goal in both CD and UC must be to restore the patient's QoL, because IBD can have a profound impact on PROs such as QoL, disability, or fatigue ( 17,170,171 ). Th e primary therapeutic target to achieve this in both UC and CD patients must be to achieve the composite end point of clinical/symptomatic and endoscopic remission, while also addressing the patient's individual goals ( 11,12 ).…”

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

“…Tumor necrosis factor-α (TNFα) antagonists are effective for the treatment of inflammatory bowel diseases, demonstrating improvement in patients' quality of life, and reductions in surgeries and hospitalizations. 1 However, around 10–30% of patients do not respond to the initial treatment and 23–46% of patients lose response over time. Determining whether the reason for failure is a primary or secondary non-response is paramount to successfully treat these patients.…”

Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?

“…Despite the benefit of anti-TNF therapy in a broad panel of inflammatory diseases, it has been well documented that the TNF inhibitors may present controversial effects in non-responder patients; this means patients who previously responded to the treatment but posteriorly, they are treatment-refractory and susceptible to infection from some bacteria such as Legionella pneumonia and Listeria monocytogenes [ 15 , 85 ]. Even more, the side effects in some cases may also include Mycobacterium tuberculosis and hepatitis B reactivation, anti-TNF inhibitor antibodies, and neurological impact [ 15 , 92 , 93 ]. In some cases, the side effects may be overcome by stopping the administration or changing the inhibitor agent.…”